Humanin: A Novel Central Regulator of Peripheral Insulin Action by Muzumdar, Radhika H. et al.
Humanin: A Novel Central Regulator of Peripheral Insulin
Action
Radhika H. Muzumdar
1,2, Derek M. Huffman
2, Gil Atzmon
2, Christoph Buettner












1Department of Pediatrics, Children’s Hospital at Montefiore, Institute for Aging Research, Diabetes Research and Training Center, Albert Einstein College of Medicine,
Bronx, New York, United States of America, 2Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America, 3Department of
Medicine, Mount Sinai School of Medicine, New York, New York, United States of America, 4Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein
College of Medicine, Bronx, New York, United States of America, 5Department of Pediatrics, Mattel Children’s Hospital, Los Angeles, California, United States of America
Abstract
Background: Decline in insulin action is a metabolic feature of aging and is involved in the development of age-related
diseases including Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s disease (AD). A novel mitochondria-associated peptide,
Humanin (HN), has a neuroprotective role against AD-related neurotoxicity. Considering the association between insulin
resistance and AD, we investigated if HN influences insulin sensitivity.
Methods and Findings: Using state of the art clamp technology, we examined the role of central and peripheral HN on
insulin action. Continuous infusion of HN intra-cerebro-ventricularly significantly improved overall insulin sensitivity. The
central effects of HN on insulin action were associated with activation of hypothalamic STAT-3 signaling; effects that were
negated by co-inhibition of hypothalamic STAT-3. Peripheral intravenous infusions of novel and potent HN derivatives
reproduced the insulin-sensitizing effects of central HN. Inhibition of hypothalamic STAT-3 completely negated the effects
of IV HN analog on liver, suggesting that the hepatic actions of HN are centrally mediated. This is consistent with the lack of
a direct effect of HN on primary hepatocytes. Furthermore, single treatment with a highly-potent HN analog significantly
lowered blood glucose in Zucker diabetic fatty rats. Based upon the link of HN with two age-related diseases, we examined
if there were age associated changes in HN levels. Indeed, the amount of detectable HN in hypothalamus, skeletal muscle,
and cortex was decreased with age in rodents, and circulating levels of HN were decreased with age in humans and mice.
Conclusions: We conclude that the decline in HN with age could play a role in the pathogenesis of age-related diseases
including AD and T2DM. HN represents a novel link between T2DM and neurodegeneration and along with its analogues
offers a potential therapeutic tool to improve insulin action and treat T2DM.
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Introduction
Humanin (HN) is a 24 amino acid polypeptide (Met- Ala- Pro-
Arg- Gly- Phe- Ser- Cys- Leu- Leu- Leu- Leu- Thr- Ser- Glu- Ile-
Asp- Leu- Pro- Val- Lys- Arg- Arg- Ala; M.W.=2656.3 Da) that
was first identified from a cDNA library from the surviving
neurons of human Alzheimer’s disease (AD) brain [1]. Since its
initial discovery, several cDNAs sharing sequence homology to
HN have been identified in plants, nematodes, and rodents
demonstrating that HN is evolutionarily conserved [2]. HN is
transcribed from an open reading frame within the mitochondrial
16S ribosomal RNA. Endogenous HN is both an intracellular and
secreted protein and has been detected in normal mouse testis and
colon at specific stages of development [3]. In addition to brain,
colon and testis, we have shown the presence of HN by western
blot in rodent heart, ovary, pancreas and kidney (unpublished
data). In addition, our group has demonstrated the presence of
HN in cerebral spinal fluid (CSF), seminal fluid and plasma, with
levels in the biologically active range (Cohen & Hwang,
unpublished data).
Despite little being known regarding the regulation of HN
production in vivo, the major role of HN is believed to be promoting
cell survival. Indeed, HN has a well-described role in neuroprotec-
tion against cell death associated with AD [1], from AD-specific
insults [4], prion induced apoptosis [5] and chemically-induced
neuronal damage [6]. Interestingly, a highly-potent analogue of
HN, termed HNG, (HN in which the serine at position 14 is
replaced by glycine), reverses the learning and memory impairment
induced by scopolamine in mice [6] and also has rescue activity
against memory impairment caused by AD-related insults in vivo [7].
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6334The protection of HN from AD-related cytotoxicity has also been
demonstrated in non-neuronal cells such as cerebrovascular smooth
muscle [8], rat phaeochromocytoma cells and lymphocytes under
serum-deprived conditions [9].
The anti-apoptotic potential of HN appears to be dependent
upon the formation of homodimers, as interfering with this process
completely blocks its ability to suppress cell death [10]. Once
dimerized, HN directly interacts with a variety of pro-apoptotic
proteins, including Bax-related proteins [2] and insulin-like growth
factor binding protein-3 (IGFBP-3) [11]. It has been shown that
HN protects against apoptosis by binding pro-apoptotic Bax,
inhibiting its mitochondrial localization, and attenuating Bax-
mediated apoptosis activation [2]. HN was also shown to act
directly on Bax in isolated mitochondria suggesting that a cell
surface receptor may not be required for its anti-apoptotic action
[2] though some studies suggest involvement of the cell surface
receptor FPRL-1 [12,13]. A recent study has demonstrated that
HN protects neurons by binding to a complex or complexes
involving CNTFR/WSX-1/gp130 [13]. Moreover, neuronal
protection by HN involves activation of tyrosine kinases and
STAT-3 phosphorylation [14], while the inhibition of tyrosine
kinases or the use of dominant negative STAT3 prevented the
anti-apoptotic action of HN. Furthermore, HN delays apoptosis in
K562 cells by downregulation of p38 MAP kinase [15] and
prevents cell death in a constitutively activated Jun N-terminal
kinase (JNK) cell line, suggesting that an important mechanism of
cell protection could be via interfering with JNK activity [16].
The interaction between HN and IGFBP-3 is especially
interesting since IGFBP-3 and HN have opposing roles on cell
survival, such that HN protects against while IGFBP-3 induces cell
death [17]. We previously demonstrated that HN physically binds
with IGFBP-3 and that this interaction prevents the activation of
caspases [11]. More recently, we showed that IGFBP-3,
independent of IGF-1, induces insulin resistance both at the liver
and periphery through the hypothalamus as well as by direct
action [18,19]. Based upon the molecular interaction between HN
and IGFBP-3 and the emerging link between AD and insulin
resistance [20], we hypothesized that HN, in addition to its
neuroprotective roles, may serve as a centrally-acting regulator of
glucose homeostasis. In a series of experiments, we examined the
role of HN in glucose metabolism and its potential mechanism of
action, including its interaction with IGFBP-3, by using HN and a
variety of HN analogs. We also examined if there were changes in
the levels of HN in circulation and in tissues with age.
Methods
Animal preparation for in vivo experiments
We studied 92 three-month-old male Sprague2Dawley rats (S–
D, Charles River Laboratories) and 9 three-month old Zucker
Diabetic Fatty (ZDF) rats (Harlan). Rats were housed in individual
cages and subjected to a standard light2dark cycle (12L:12D).
Depending on the study group the rats received ICV and IV
catheters. For ICV studies, S–D rats were prepared for clamps as
described in Fig. 1A. Three weeks before the in vivo studies,
catheters were implanted in the third cerebral ventricle [21]. One
week before clamp experiments, catheters were placed in the right
internal jugular vein and left carotid artery [22]. ZDF rats were
allowed to acclimate for 1 wk and glucose levels were monitored
for the appearance of diabetes (.200 mg/dL). All animals became
diabetic within 2 weeks of arrival. Once diabetic, animals had
indwelling catheters inserted into the right internal jugular vein
and the left carotid artery under anesthesia. Recovery was
monitored until body weight was within 3% of the pre-operative
weight (,5–6 days). The study protocol was reviewed and
approved by the Institutional Animal Care and Use Committee
of the Albert Einstein College of Medicine.
In vivo Intra-cerebro ventricular and Intravenous studies,
analysis of glucose fluxes and hormone measurements
Intra-cerebro ventricular (ICV) studies: Food was removed for ,5h
before the in vivo protocol. All studies lasted 360 min and included
a 120-min equilibration period, a 120-min basal period for
assessment of the basal glucose turnover, and a 120-min
pancreatic or hyperinsulinemic clamp period. A primed-continu-
ous ICV infusion of HN, F6AHN (total dose of 20 ug),
dimerization deficient (DD) HN, STAT-3 inhibitor (75 pmol) ,
or artificial cerebro-spinal fluid (aCSF) was initiated at t=0 and
maintained throughout the experiment (Fig. 1A) by an infusion
pump. Pancreatic insulin-clamp studies (1 mU/kg/min), approx-
imating the basal fasting state with circulating insulin levels around
1.4 ng/ml, or euglycemic-hyperinsulinemic clamps (3 mU/kg/
min), corresponding to the post-prandial state with circulating
insulin levels around 4.5 ng/ml, were performed in conscious,
unrestrained, catheterized rats for the last 120 min as described
previously [19,22].
In the intravenous (IV) studies, HN (0.375 mg/kg/hr), IGFBP-3
(0.06 mg/kg/hr), or analogs of HN such as F6AHN (0.375 mg/
kg/hr) and HNGF6A (0.05 mg/kg/hr) were infused intravenously
and hyperinsulinemic clamps were performed as described
previously [18]. The HN analog F6AHN has a single amino acid
substitution of alanine for phenylalanine in position 6; this
substitution abrogates IGFBP-3 binding. Another HN analog
HNG has an amino acid substitution at position 14 (glycine for
serine) that increases the biologic potency by ,1000 fold. A third
HN analog, HNGF6A, contains both of these substitutions at
positions 6 and 14, resulting in a potent non-IGFBP-3 binding
peptide. DD HN analog has an amino acid substitution of alanine
with serine at position 7 resulting in a peptide that fails to
dimerize. A subgroup of animals that received IV HNGF6A also
received ICV STAT-3 inhibitor [23].
The protocol followed during the insulin clamp study was
similar to that previously described. Briefly, a primed-continuous
infusion of regular insulin ( 1 or 3 milliunits/kg?min) was
administered, and a variable infusion of a 25% dextrose solution
was started and periodically adjusted to clamp the plasma glucose
concentration at 7–8 mM. Somatostatin (1.5 mg/kg?min) was also
infused in all the groups to prevent endogenous insulin secretion
and to control for possible effects of the ICV infusions on the
endocrine pancreas. Estimation of glucose, glucose fluxes, insulin
and FFA were done as described previously [19,22]. HN
measurements were performed by an in-house ELISA utilizing
Figure 1. Protein level of the rat homolog to HN, termed rattin
(RN), in metabolically-relevant tissues in male S–D rats. A total
of 30 mg of rat skeletal muscle (lane 1), liver (lane 2), epididymal fat
(lane 3) and hypothalamic protein (lane 4) and 1.5 ng of synthetic RN
peptide (lane 5) were loaded. RN protein was detected in muscle, liver
and hypothalamus but not in epididymal fat (lane 3).
doi:10.1371/journal.pone.0006334.g001
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0.1 ng/ml (Hwang and Cohen, Personal communication).
Chronically catheterized ZDF rats were studied while awake,
unrestrained and unstressed. Early in the morning, ZDF rats had
food removed from their hoppers and animals were prepared for
the procedure. Initially, rats were infused with a 100 ug HNGF6A
bolus (0.5 ug/uL) (n=5) or 200 uL saline (n=4) into the carotid
artery. Glucose levels were then monitored for 4 hours by
sampling venous blood and glucose levels were determined in
whole blood using glucose strips (One Touch Ultra, LifeScan Inc.,
Milpitas, CA).
Signaling studies and Protein analysis
For acute signaling studies, rats were injected ICV with either
aCSF, 20 ug of HN or F6AHN (dissolved in aCSF) over 5 min,
and sacrificed 30 min later. At sacrifice, liver, skeletal muscle
(quadriceps) and mediobasal hypothalamus (MBH) were rapidly
excised and snap frozen in liquid nitrogen. The MBH was
identified caudally by the mammillary bodies, rostrally by the optic
chiasm, laterally by the optic tract, and superiorly by the apex of
the hypothalamic third ventricle. Protein was then extracted from
tissues and western blot analysis was performed as described
previously [23]. Briefly, following incubation with the appropriate
antibody, membranes were scanned using the LI-COR Odyssey
(LI-COR, Lincoln, NE, USA) and quantified using Odyssey 2.0




Insulin receptor (IR) and b-Tubulin were all obtained from Cell
Signaling (Danvers, MA). The Dot blots were performed by
blotting 50 ng of HN, HN-analogues, and IGF on nitrocellulose,
incubating with 125-I-labeled-IGFBP-3, autoradiography and
scanning. RN protein levels in tissues were measured using a
rabbit polyclonal antibody to RN (1:500, Sigma, St. Louis, MO)
utilizing standard Western blotting techniques and imaged by
chemiluminesence using a FujiFilm LAS-3000 bioimager (Valhal-
la, NY).
Isolation of primary hepatocytes, hepatic glucose
production and signaling pathways
Single-cell suspensions of hepatocytes were obtained from
perfusions of Sprague–Dawley rats using the procedure of Berry
[24] and the perfusion mixture of Leffert et al [25]. Hepatocyte
glucose production was estimated after a 24 hr treatment with
HN, F6AHN or saline as described before [26]. In a separate set of
experiments, hepatocytes were lysed, and protein extracted in
RIPA lysis buffer at 30, 60 and 360 min post treatment with HN,
F6AHN and saline. The cell lysates were then subject to western
blotting for evidence of STAT-3 and AKT activation.
Statistical Analyses
All values shown are expressed as means6SE. When comparing
two groups for analysis such as protein densitometry, independent
two-tailed t test was used. For variables such as HGP or Rd
involving more than 2 groups, one way ANOVA was used. When
pre vs. post clamp comparisons for variables such as glycolysis and
glycogen synthesis were made, two- way ANOVA (group6time)
was used. For time course measures such as GIR, ANOVA with
repeated measures on time was used. For each statistically
significant F value observed for the main effect or interaction, a
two-tailed post hoc test (Tukey’s) was applied to determine
individual differences between means. Differences were considered
to be statistically significant when P#0.05.
Results
HN is present in metabolically relevant tissues
To confirm the presence of rattin (RN), the rat homolog to HN,
we analyzed the expression level of RN protein in metabolically
relevant tissues including the skeletal muscle, liver, fat and
hypothalamus. As demonstrated by western blot (Fig. 1), RN is
expressed in muscle, liver and hypothalamus but was not detected
in epididymal fat. The observed band for RN in the hypothalamus
runs slightly higher than in other tissues. This is consistent with the
observation by Tajima et al. [3] who showed that HN derived
from lipid-enriched tissues in rodents produces a HN band that is
shifted slightly higher (2–3 kD) than other tissues and that lipid
extraction resulted in downward migration of the HN band.
Furthermore, similar to HN in mouse tissues, endogenous RN
runs at a slightly higher molecular weight than synthetic human
peptide due to the presence of a C-terminal tail on endogenous
RN.
ICV HN increases systemic insulin sensitivity
Under basal insulin levels during pancreatic-euglycemic clamp
(1.4260.08 vs. 1.4160.03 ng/ml in controls vs. HN, N.S), a
higher glucose infusion rate (GIR) was required to maintain
euglycemia in the groups that received ICV HN (Fig. 2B). Glucose
kinetics using tracer methodology demonstrated that the need for a
higher rate of glucose infusion (Fig. 2B) was due to enhanced
hepatic insulin sensitivity, leading to a significant decrease in
hepatic glucose production (HGP) (P,0.05, Fig. 2C).
Under physiologic hyperinsulinemic clamp conditions (insulin
levels of 3.960.2 vs. 4.660.6 ng/ml in controls vs. HN, N.S), GIR
was significantly higher in the ICV HN group (P,0.05, Fig. 2D).
This effect was secondary to suppression of HGP (P,0.05, Fig. 2E,
F) and enhanced skeletal muscle glucose uptake (P,0.05, Fig. 2G,
H), features of enhanced hepatic and peripheral insulin sensitivity.
HN was undetectable in the circulation during ICV infusion
confirming that there was no leak of ICV infused HN (data not
shown). The degree of suppression of HGP, an indicator of hepatic
insulin sensitivity, was significantly higher in HN infused groups
(12.160.9 to 4.760.4 in controls vs. 12.860.7 to 2.360.4 in HN
infused groups, P,0.05). The dramatic increase in GIR with
central HN is not only due to effects on HGP, but also through an
increase in peripheral glucose uptake (P,0.05, Fig. 2G–H). Using
tracer methodology, we demonstrate that the HN-induced
increase in glucose uptake is associated with increases in both
glycolysis and glycogen synthesis (P,0.05, Figs. 2I & 2J).
Furthermore, insulin-induced suppression of free fatty acid (FFA)
levels was significantly enhanced with ICV HN (Fig. 2K),
reflecting an overall improvement in peripheral insulin sensitivity.
In addition, we assessed the effects of DD HN on glucose
metabolism since dimerization is an essential step in the
cytoprotective effects of HN [27]. The infusion of DD HN ICV
had no effect on overall glucose metabolism (Fig. 2D–H).
Specifically, there were no differences in GIR (Fig. 2D), HGP
(Fig. 2E, F) or peripheral glucose uptake (Fig. 2G, H) between the
groups that received the DD HN and controls.
Central HN activates mediators of insulin action in
skeletal muscle
Consistent with enhanced glucose uptake, insulin signaling in
the skeletal muscle was significantly increased during ICV HN
infusion, in spite of similar circulating insulin levels (Fig. 2L). We
observed increased phosphorylation of the insulin sensitive AKT
(pAKT
S473) and Acetyl-CoA Carboxylase (pACC
Ser79) in skeletal
muscle with HN. We also studied potential direct effects of HN on
Humanin and Insulin Action
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6334Figure 2. ICV HN increases peripheral insulin sensitivity. A) Schematic representation of the experimental design for the ICV studies; the
upper panel demonstrates the time line for the surgical procedures and the lower panel demonstrates the protocol on the day of the clamp. B)
Glucose infusion rate (GIR) and C) Hepatic glucose production (HGP) and degree of suppression of HGP by artificial cerebrospinal fluid (aCSF) and
0.16 mg/kg/min HN infusions (n=5 each) during a basal pancreatic clamp. D) GIR, E) HGP and F) degree of HGP suppression during a
hyperinsulinemic clamp with ICV infusion of aCSF, HN and a DDHN peptide (n=7 each). G) Time course and H) last hour average of effects of ICV
aCSF, HN and DDHN on peripheral glucose uptake during a hyperinsulinemic clamp. Effect of aCSF (black bars) and HN (white bars) on I) glycolysis, J)
glycogen synthesis, and K) suppression of free fatty acids (FFA) in response to insulin. L) pAKT and acetyl CoA carboxylase (ACC) in skeletal muscle
during insulin clamp in response to ICV aCSF and HN (n=7 each). Values are means6SE. *Significantly different from other experimental groups,
P,0.05.
doi:10.1371/journal.pone.0006334.g002
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liver pAKT
S473, PGC-1b, Fatty Acid Synthase (FAS), p38 MAPK,
CREB or ACC were demonstrable between the HN and control
groups (data not shown).
Activation of STAT-3 in the hypothalamus is critical for
the effects of HN on glucose metabolism
Since HN has been shown to work via STAT-3 activation, we
examined the effect of acute HN ICV infusion on STAT-3
phosphorylation (pSTAT-3
Tyr705) in the hypothalamus. As
presented in Fig. 3A, HN infusion resulted in a 10-fold increase
in STAT-3 phosphorylation in hypothalamic tissues within an
hour of ICV HN infusion (P,0.05). In contrast, no effect was
observed on phosphorylation levels in other signaling kinases in
the hypothalamus including pAKT
S473 (Fig. 3B). To test the role
of STAT-3 activation in the mediation of HN actions, we co-
infused HN along with a STAT-3 inhibitor [28] ICV and showed
that the effects of HN are completely attenuated in the presence of
the STAT-3 inhibitor (Fig. 3C–3F). The hypothalamic delivery of
the STAT-3 inhibitor showed no effect on its own, yet completely
abolished HN-induced suppression of HGP and peripheral glucose
uptake.
Hypothalamic IGFBP-3 tempers the effects of HN on
hepatic insulin action
We have previously shown that IGFBP-3 is present in the
hypothalamus and inhibits hepatic insulin action via a hypotha-
lamic mechanism [19]. We have separately shown that IGFBP-3
also binds HN and antagonizes its survival effects [11]. To assess if
IGFBP-3 attenuates the effects of HN on insulin action, we utilized
a series of HN analogues that do not bind to IGFBP-3 (Fig. 4A).
Non-IGFBP-3 binding homologues are more potently active as a
direct result of the loss of IGFBP-3 binding, as exemplified in
apoptosis studies using mouse embryo fibroblasts from IGFBP-3
knockout mice (Fig. 4B). We hypothesized that if IGFBP-3 inhibits
the effects of HN on glucose metabolism, non-IGFBP-3 binding
analogues of HN would have a greater effect. As expected, infusion
of IGFBP-3 ICV led to a decrease in GIR, but both ICV HN and
the non-BP3-binding HN analogue (F6AHN) increased GIR
(P,0.05, Fig. 4C). Remarkably, under similar insulin levels,
(3.960.2, 4.660.6 and 5.061.0 ng/ml in controls, HN, and
F6AHN respectively, N.S) F6AHN enhanced hepatic insulin
action to an even greater extent than HN. This effect was
primarily due to a near-complete inhibition of HGP (from
12.160.9 to 4.760.4 in controls vs. 11.060.3 to 0.661.0 in
F6AHN , P,0.05, Fig. 4D–E), effects that cannot be elicited in
rodents even with pharmacological levels of insulin.
Peripheral administration of a potent HN analog
improves insulin sensitivity
We then assessed if peripheral administration of HN can
reproduce the central effects of HN. We infused HN or F6AHN
intravenously (at a rate of 0.375 mg/kg/hr) during a hyperinsu-
linemic clamp to examine the effect of these compounds on
glucose fluxes. HN and F6AHN, though potent when given
centrally, did not significantly alter insulin action when infused
intravenously at the given dose (data not shown). We then
engineered a more potent non-IGFBP-3 binding analogue of HN,
with two substitutions, S14G (HNG, an analog shown to be more
potent), along with F6A (resulting in non-IGFBP3 binding)
resulting in a more potent, non-IGFBP-3-binding- analogue of
HN, termed HNGF6A. When HNGF6A was infused intrave-
nously (0.05 mg/kg/hr) during a hyperinsulinemic clamp (insulin
levels of 4.560.3 vs. 4.160.2 ng/ml in controls vs. HNGF6A,
N.S), glucose infusion rates during clamp were significantly higher
(P,0.05, Fig. 5A) and this was due to an enhancement of
peripheral glucose uptake and suppression of HGP (P,0.05,
Fig. 5B, Fig. 5C). Thus, intravenous HNGF6A, a more potent
analog of HN, is able to reproduce the potent effects of central HN
on insulin sensitivity.
Effects of the potent HN analog, HNGF6A on hepatic
insulin sensitivity are mediated through the
hypothalamus
To examine the role of the hypothalamus in mediating the
effects of peripherally administered HN analogue, we infused
HNGF6A peripherally in the presence of hypothalamic inhibition
of STAT-3 and studied glucose fluxes under insulin clamps. The
insulin levels achieved were similar and glucose was clamped at
basal levels. In the presence of hypothalamic STAT-3 inhibition,
the GIR in response to peripheral HNGF6A was similar to
controls (Fig. 6A). Furthermore, the effect on HGP was completely
blocked by central STAT-3 inhibition (Fig. 6B) while effects on
skeletal muscle were attenuated (Fig. 6C). This suggests that the
effect of peripherally administered HN analog on hepatic insulin
action is through the hypothalamus, while the effects on skeletal
muscle are due to both central and direct actions.
No direct effect of HN on hepatic insulin action in vitro
We further probed a possible direct effect of HN on the liver by
incubating rat hepatocyte explant cultures with and without HN in
vitro. When HN was added to the media, there was no effect on
glucose production rates (Fig. 6D). We then tested the effects of
HN on primary hepatocytes including its ability to induce
phosphorylation of STAT-3, as hepatic STAT-3 activation has
been linked to insulin action [29]. HN and F6AHN did not elicit
significant changes in pAKT
S473 or pSTAT-3
Tyr705 in hepatocytes
(data not shown), compatible with the lack of effect we
demonstrated on glucose production in hepatocytes.
HNGF6A significantly lowers blood glucose in Zucker
diabetic fatty (ZDF) rats
ZDF rats with a mean glucose level of 293.1618.7 mg/dL
received a single intravenous injection of 100 ug HNGF6A bolus
(0.5 ug/uL) (n=5) or 200 uL saline (n=4). As shown in Fig. 7,
HNGF6A significantly lowered glucose levels in this diabetic
model with effects seen by approximately 90 min and persisting
for the remaining 4 hours of blood sampling (P,0.05). Indeed,
glucose levels decreased by nearly 50% in ZDF rats treated with
HNGF6A but were unaltered in rats that received saline.
Age associated changes in levels of HN in tissues
HN levels in plasma were measured in young and old mice and
across age in humans. HN levels decreased with age in both mice
(Fig. 8A, P,0.05) and humans (Fig. 8B, P,0.05). In addition, the
expression of the HN homolog RN tended to be decreased with
age in the hypothalamus (P=0.12) and was significantly lower in
skeletal muscle from old rats (Fig. 8C, P,0.05).
Discussion
We demonstrate here that infusion of HN into the third
ventricle of rats, and peripheral infusion of the potent HN analog
HNGF6A, improves both hepatic and peripheral insulin sensitiv-
ity. We show that, similar to effects on apoptosis, dimerization of
HN is essential for its actions on glucose metabolism. We also
Humanin and Insulin Action
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6334Figure 3. Central effects of HN on glucose metabolism involve hypothalamic STAT-3 activation. A) Effects of ICV HN or aCSF on pSTAT-
3
Tyr705 levels in hypothalamic protein extracts. B) Effects of ICV HN and F6AHN on the levels of totalSTAT-3, pAKT
S473, insulin receptor (IR) and
pAMPK
Thr172 in the hypothalamus (aCSF -black bars, HN -white bars, F6AHN-grey, n=5 each). Effects of a STAT-3 inhibitor co-infused ICV with HN or
aCSF (n=6 each) on C) GIR, D) peripheral glucose uptake, and E) HGP and degree of suppression of HGP. Values are means6SE. *Significantly
different from other experimental groups, P,0.05.
doi:10.1371/journal.pone.0006334.g003
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the insulin-sensitizing action of HN. Furthermore, we show that
the effects of HN on glucose metabolism are tempered by binding
of HN to IGFBP-3 in the hypothalamus, as central infusion of a
non-IGFBP-3 binding analog, F6AHN, resulted in a more potent
effect on insulin action than HN. We also show that the effect of
peripherally administered HN analog on the liver is entirely
through the hypothalamus, while the effect on the skeletal muscle
may involve both direct and central effects.
The critical role of the MBH in mediating hepatic glucose
metabolism has been unraveled by prior studies with leptin, insulin
and IGF-1. In the studies presented here, the hypothalamus
appears to play a key role in mediating the effects on hepatic
insulin sensitivity in response to the administration of both central
Figure 4. IGFBP-3 modulates the effects of HN on insulin sensitivity. A) IGFBP-3 binding of HN and HN analogues measured by densitometry
of dot blots probed with radiolabeled IGFBP-3 (Ins=Insulin). B) Mouse embryonic fibroblasts generated from wild-type or IGFBP-3 knockout mice
were incubated in serum-free media for 24 h followed by incubation with 100 nM HNG or HNGF6A for 24 h. Apoptosis was assessed by ELISA for
fragmentation of histone-associated DNA. (n=4). Effects of ICV IGFBP-3, HN or F6AHN during a hyperinsulinemic clamp (n=6 each)on C) GIR, D) HGP
and E) degree of suppression of HGP. *Significantly different from other experimental groups, P,0.05.
doi:10.1371/journal.pone.0006334.g004
Humanin and Insulin Action
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administered HN dramatically increased GIR not only due to
effects on HGP, but also through an increase in peripheral glucose
uptake, demonstrating that HN is the first centrally-acting peptide
to favorably modulate glucose uptake in skeletal muscle. The
autonomic nervous system may serve as the efferent in mediating
the effects of HN on peripheral glucose metabolism. Hypothalamic
nuclei have been shown to influence HGP through the vagus nerve
[30], while leptin and IGF-1 have been shown to effect output
through the sympathetic nervous system [31,32]. More studies are
needed to specifically evaluate the role of autonomic nervous
system in mediating the effects of HN.
This study also provides evidence that HN and IGFBP-3 not
only have opposing roles on apoptosis but also on peripheral
insulin action via the hypothalamus. The opposing roles of these
two peptides on glucose homeostasis and apoptosis are especially
interesting when one considers the close relationship between
insulin resistance and cell survival in AD. In fact, defects in glucose
utilization, a striking reduction in insulin receptor mRNA levels,
and attenuated insulin signaling, as evidenced by decreased IRS-1,
PI3K, and pAKT have been demonstrated in AD [33]. On the
other hand, insulin sensitizers such as thiazolinediones improve
cognitive function in mouse models as well as humans with early
AD, highlighting the role of insulin resistance in this condition
[34]. While IGFBP-3 production is increased in AD brain [35],
HN is expressed in the non-apoptotic hippocampal regions of
Alzheimer’s patients’ brains and is absent in senile plaques [3].
Taken together, the improvement in insulin sensitivity demon-
strated with central HN may be one of the primary mechanisms by
which HN regulates cell survival and, therefore, may provide an
additional potential mechanism by which HN is protective against
AD.
Molecular manipulations of HN at key amino acids have been
shown to offer significant increases in its potency or chemical
characteristics. For instance, a change at position 14, [Gly
14]-HN
(S14G, HNG), has been shown to enhance neurosurvival activity
and also offers added protection against memory impairment [36]
and stroke [37]. A substitution of phenylalanine in the 6
th position
with alanine (F6A, F6AHN) alters the binding of HN to IGFBP-3
and we show here that this substitution significantly enhances its
central effect on glucose metabolism. Interestingly a novel HN
analog termed HNGF6A, which we created by combining both
changes at position 6 and 14, dramatically increases its ability to
modulate insulin action and offers a mode of administration that is
more clinically applicable. We also show here that HNGF6A not
only improves insulin sensitivity during a clamp, but also
significantly improves blood glucose levels in ZDF rats with a
single dose. The potential of HNGF6A as a treatment for T2DM
is an exciting observation which warrants further investigation,
including chronic treatment of diabetic models with this peptide.
Another important observation from this study is that intact
STAT-3 signaling in the hypothalamus is necessary for the effects
of HN on glucose metabolism. This is in partial agreement with
prior studies which have pinpointed the mechanism by which HN
confers neuronal protection to the activation of tyrosine kinases
and STAT-3 phosphorylation [14]. STAT-3 phosphorylation and
activation in the hypothalamus is well known to play a pivotal role
in the regulation of energy homeostasis. For example, neuronal
STAT-3 KO mice are morbidly obese, hyperphagic and diabetic
[38]. This effect is due at least in part to attenuated leptin signaling
Figure 5. Effects of peripheral administration of the potent HN analog, HNGF6A, on glucose metabolism. Effect of IV saline, F6AHN and
HNGF6A (n=6 each) on A) GIR, B) HGP, and C) glucose uptake. Values are means6SE. *Significantly different from other experimental groups,
P,0.05.
doi:10.1371/journal.pone.0006334.g005
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by co-infusion of a STAT-3 inhibitor with leptin which resulted in
attenuation of the actions of leptin on food intake and glucose
metabolism [23]. Likewise, we show that co-infusion of a STAT-3
inhibitor with HN into the third ventricle completely attenuates
the ability of HN to modulate peripheral insulin action. Indeed,
when STAT-3 signaling was inhibited in the hypothalamus, the
effects of peripherally administered HN analog on liver was
completely abolished, once again emphasizing the role of the
hypothalamus in mediating the hepatic effects of HN and its
analogues. Furthermore, the absence of any effect on phosphor-
ylation levels of other signaling kinases, including AKT, demo-
nstrates that the effects of HN are independent of hypo thalamic
insulin signaling.
The potential of anti-apoptotic therapy for neurodegeneration
has been gaining attention [39], and growth factors of various
types including IGF-1 and other neuro-survival peptides [39,40]
have been considered. While the role of HN in neuroprotection
has been substantially characterized and HN has been proposed to
have enormous therapeutic potential for neurodegenerative
diseases, the studies described here comprise the first evidence
demonstrating a role for HN in glucose metabolism. Considering
that diseases associated with aging such as T2DM and AD have
been proposed to be associated with mitochondrial dysfunction
[41,42], it is especially interesting that the mitochondrial-derived
peptide HN modulates them. In summary, these data demonstrate
for the first time that HN regulates peripheral insulin action. The
link between the decrease in circulating levels of HN as well as
levels in hypothalamus and skeletal muscle with age, in parallel
with the increase in age- associated diseases such as AD and
T2DM is extremely intriguing and warrants further investigation.
Figure 7. Effect of a single IV dose of HNGF6A on blood
glucose levels in chronically catheterized, unstressed Zucker
diabetic fatty (ZDF) rats over 4 hours. *Significantly different than
saline controls, P,0.05.
doi:10.1371/journal.pone.0006334.g007
Figure 6. Effects of IV HNGF6A in the presence of hypothalamic STAT-3 inhibitor on A) GIR, B) HGP and C) peripheral glucose
uptake. D) Effect of HN on glucose production from primary isolated hepatocytes treated with (+), or without (2) insulin. Values are means6SE.
*Significantly different from other experimental groups, P,0.05.
doi:10.1371/journal.pone.0006334.g006
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therapeutic options for prevention or treatment of at least two age-
related diseases, namely impaired carbohydrate metabolism/
T2DM and neurodegeneration.
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